Tech Company Financing Transactions

LEXEO Therapeutics Funding Round

LEXEO Therapeutics, operating out of New York, secured $100 million from D1 Capital Partners, Eventide Asset Management and Alexandria Venture Investments.

Transaction Overview

Company Name
LEXEO Therapeutics
Announced On
9/10/2021
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors

D1 Capital Partners (Lead Investor) (Daniel Sundheim)

Eventide Asset Management (Lead Investor) (Joy Ghosh)

Alexandria Venture Investments

CAM Capital

Gray's Creek Capital Advisors

Invus

Janus Henderson Investors

Laurion Capital Management

Longitude Capital Management (Sandip Agarwala)

Lundbeckfond Ventures (Mette Agger)

Omega Funds (Bernard Davitian)

PBM Capital

Verition Fund Management

Woodline Partners

Proceeds Purpose
Proceeds from the financing will support the development of LEXEO's expanded pipeline, including recently acquired cardiac gene therapy programs and additional preclinical programs focused on the genetic causes of Alzheimer's disease (LX1020 and LX1021).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
430 East 29th St. 14th Floor
New York, NY 10016
USA
Phone
(212) 547-9879
Website
www.lexeotx.com
Email Address
[email protected]
Overview
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world's most devastating genetic and acquired diseases.
Profile
LEXEO Therapeutics LinkedIn Company Profile
Social Media
LEXEO Therapeutics Company Twitter Account
Company News
LEXEO Therapeutics News
Facebook
LEXEO Therapeutics on Facebook
YouTube
LEXEO Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nolan Townsend
  Nolan Townsend LinkedIn Profile  Nolan Townsend Twitter Account  Nolan Townsend News  Nolan Townsend on Facebook
Chief Medical Officer
Jay Barth
  Jay Barth LinkedIn Profile  Jay Barth Twitter Account  Jay Barth News  Jay Barth on Facebook
Chief Scientific Officer
Ronald Crystal
  Ronald Crystal LinkedIn Profile  Ronald Crystal Twitter Account  Ronald Crystal News  Ronald Crystal on Facebook
VP - Bus. Development
Christopher Holterhoff
  Christopher Holterhoff LinkedIn Profile  Christopher Holterhoff Twitter Account  Christopher Holterhoff News  Christopher Holterhoff on Facebook
VP - Operations
Paul McCormac
  Paul McCormac LinkedIn Profile  Paul McCormac Twitter Account  Paul McCormac News  Paul McCormac on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/10/2021: Orchard venture capital transaction
Next: 9/10/2021: DotCom Therapy venture capital transaction

 

Share this article

 

News on VC Transactions

Our team works diligently to record tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.